Measurement of Perioperative Glomerular Filtration Rate
|ClinicalTrials.gov Identifier: NCT03881332|
Recruitment Status : Suspended (Recruitment not possible)
First Posted : March 19, 2019
Last Update Posted : March 25, 2020
|Condition or disease|
|Rectal Cancer Colon Cancer|
The considerable morbidity and mortality associated with perioperative acute kidney injury (AKI) is well documented and known to complicate recovery from surgery.
Accurate, direct measurements of glomerular filtration rate (GFR) may provide a tool to monitor perioperative onset of rapidly changing renal function. This may subsequently lead to design of randomized controlled trials examining the effects of earlier intervention with the aim to reduce the incidence of perioperative AKI.
Recently a protocol for continuous infusion of low-dose iohexol (CILDI) as a measure of GFR in stable patients over a range of GFR (28-128 mL/min/1.73 m2) has been developed. Accuracy of this infusion protocol was confirmed with the single bolus injection (SBI) method. Data also showed that the continuous infusion protocol of low-dose iohexol is an accurate and precise method when measuring changing GFR even in critical ill patients with variable AKI risks. Accordingly, SBI and CILDI together now allow us to explore unanswered research questions related to perioperative change in renal function.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||25 participants|
|Target Follow-Up Duration:||3 Days|
|Official Title:||Clinical Observational Study Using Iohexol to Measure Perioperative Glomerular Filtration Rate in Patients Undergoing Robotic Surgery for Rectum or Large Bowel Cancers|
|Actual Study Start Date :||December 26, 2019|
|Actual Primary Completion Date :||February 29, 2020|
|Estimated Study Completion Date :||December 22, 2020|
- Glomerular filtration rate [ Time Frame: 72 hours ]Measured glomerular filtration rate
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03881332
|University Hospital of North Norway|
|Tromsø, Troms, Norway, 9038|
|Study Chair:||Lars Marius Ytrebo, PhD||University Hospital of North Norway|